Welcome to our dedicated page for RELIEF THERAPEUTICS HLDG news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on RELIEF THERAPEUTICS HLDG stock.
RELIEF THERAPEUTICS Holding SA, traded as RLFTF, is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases. The company focuses on advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit patients. Relief Therapeutics offers a diversified portfolio of marketed products, proprietary platform technologies, and a targeted clinical development pipeline. With a mission to provide therapeutic relief to those suffering from rare diseases, Relief Therapeutics is led by an experienced team of industry leaders. Headquartered in Geneva, the company is listed on the SIX Swiss Exchange and quoted on the OTCQB.
Rhea-AI Summary
Relief Therapeutics Holding SA grants exclusive license to Eton Pharmaceuticals, Inc. for commercialization of GOLIKE products in the U.S., marking a strategic move in partnership models. The agreement includes upfront payment, sales milestones, and royalties. PKU GOLIKE's net sales exceeded $1 million in the U.S. in Q4 2023, with additional medical food line extensions for rare metabolic diseases planned for launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.08%
Tags
-
Rhea-AI Summary
Relief Therapeutics Holding SA renews a CHF 50 million Share Subscription Facility agreement with GEM Global Yield LLC, showcasing commitment to strategic transformation. The Company aims to enhance financial flexibility and development initiatives over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
-
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announced its intent to transition from direct marketing and sales to a partnership-based model to focus on R&D activities. The company aims to streamline its commercial operations and reinforce its foundational strengths, particularly affecting its GOLIKE® franchise. Relief remains committed to supporting patients benefiting from PKU GOLIKE® and is exploring potential partnerships for the continued commercialization and expansion of its franchise and the expected commercial launch of RLF-OD032 in early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announces the stepping down of CEO Jack Weinstein and the appointment of Michelle Lock as the interim CEO. Michelle Lock, a highly experienced pharmaceutical executive, will be taking over the role immediately. She has nearly 30 years of biopharmaceutical strategic, operational, and commercialization experience and has previously held executive roles at Covis Pharma Group and Acceleron Pharma Inc. Relief is excited to have Michelle lead the company and is looking forward to a new chapter under her leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
-
Rhea-AI Summary
Relief Therapeutics announces over 400,000 outstanding ADRs, a key requirement for NASDAQ listing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
News
Rhea-AI Summary
RELIEF THERAPEUTICS to present at H.C. Wainwright Global Investment Conference on Sept. 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.68%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Relief Therapeutics announces that its state-of-the-art laboratory in Balerna, Switzerland has been audited and approved by Swissmedic, the national authorization and supervisory authority for drugs and medical products. The laboratory meets Good Manufacturing Practice (GMP) standards and offers a comprehensive suite of analytical and development services. The lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with current R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
Rhea-AI Summary
Relief Therapeutics announces implementation timeline for reverse split of its ordinary shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
FAQ
What is the current stock price of RELIEF THERAPEUTICS HLDG (RLFTF)?
The current stock price of RELIEF THERAPEUTICS HLDG (RLFTF) is $4.65 as of December 20, 2024.
What is the market cap of RELIEF THERAPEUTICS HLDG (RLFTF)?
The market cap of RELIEF THERAPEUTICS HLDG (RLFTF) is approximately 55.1M.
What does RELIEF THERAPEUTICS Holding SA do?
RELIEF THERAPEUTICS Holding SA is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases.
Where is RELIEF THERAPEUTICS Holding SA headquartered?
RELIEF THERAPEUTICS Holding SA is headquartered in Geneva.
On which stock exchanges is RELIEF THERAPEUTICS Holding SA listed?
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.
What is the mission of RELIEF THERAPEUTICS Holding SA?
The mission of RELIEF THERAPEUTICS Holding SA is to provide therapeutic relief to those suffering from rare diseases.
Who leads RELIEF THERAPEUTICS Holding SA?
RELIEF THERAPEUTICS Holding SA is led by an international team of well-established, experienced biopharma industry leaders with extensive research, development, and rare disease expertise.
What are the core therapeutic areas of focus for RELIEF THERAPEUTICS Holding SA?
RELIEF THERAPEUTICS Holding SA focuses on rare skin diseases, rare metabolic disorders, and rare respiratory diseases.
How can I learn more about RELIEF THERAPEUTICS Holding SA?
For more information about RELIEF THERAPEUTICS Holding SA, please visit their website at www.relieftherapeutics.com or follow them on LinkedIn.
RELIEF THERAPEUTICS HLDG